Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Published:2022-01 Issue:1 Volume:23 Page:91-103
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Jacobson Caron A,Chavez Julio C,Sehgal Alison R,William Basem M,Munoz Javier,Salles Gilles,Munshi Pashna N,Casulo Carla,Maloney David G,de Vos Sven,Reshef Ran,Leslie Lori A,Yakoub-Agha Ibrahim,Oluwole Olalekan O,Fung Henry Chi Hang,Rosenblatt Joseph,Rossi John M,Goyal Lovely,Plaks Vicki,Yang Yin,Vezan Remus,Avanzi Mauro P,Neelapu Sattva S

Funder

Kite Pharma Inc

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Follicular lymphoma: 2018 update on diagnosis and management;Freedman;Am J Hematol,2018

2. The evolving role of targeted biological agents in the management of indolent B-cell lymphomas;Wang;Ther Adv Hematol,2017

3. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma;Maurer;Am J Hematol,2016

4. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study;Casulo;J Clin Oncol,2015

5. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma;Dreyling;J Clin Oncol,2017

Cited by 363 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies;Recent Patents on Anti-Cancer Drug Discovery;2024-12

2. CAR T-cell therapy in cancer: Integrating nursing perspectives for enhanced patient care;Asia-Pacific Journal of Oncology Nursing;2024-10

3. Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals;Future Oncology;2024-09-13

4. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies;Blood;2024-09-12

5. Mosunetuzumab for the treatment of follicular lymphoma;Expert Opinion on Biological Therapy;2024-09-11